The Four Molecules To Scale For Industrial Biotech

In an exclusive conversation ahead of their appearance at SynBioBeta 2026 on May 4-7 in San Jose, the team behind the AB4S Molecule Manifesto made the case that industrial biotechnology's twenty-year scaling problem is finally solvable, and that the answer begins with four specific molecule families.
The bioeconomy has been promising a trillion-dollar future for two decades. What it has lacked is a credible answer to a deceptively simple question: where do we actually start?

The AB4S coalition, a cross-industry group spanning L'Oréal, Evonik, BASF, Lallemand, EIT Food, and Cradle, spent the back half of 2025 trying to answer that. They screened more than 300 molecules across 40 chemical families, interviewed over 30 experts, and pressure-tested their conclusions at a workshop in Saint-Ouen, France. The result is the Molecule Manifesto, a framework that names terpenes, peptides, non-catalytic proteins, and hydroxy acids as priority families with the clearest path to scale.

Most reports of this kind pick favorites. This one filtered. Each family was evaluated against hard thresholds: total market size above one and a half billion dollars by 2030, biotech-addressable opportunity above one billion dollars, and a unit price high enough for bio-based routes to compete before full cost parity. Three lenses drove the selection, technical feasibility, economic viability, and sustainability impact, and only molecules that cleared all three survived. 

Terpenes are the quick win. A seven-to-twelve-billion-dollar market with established buyers in flavor and fragrance, and bio-production already commercial for squalane and patchoulol. Peptides are the long-game platform with premium pricing, multifunctionality, and PFAS phase-outs in cosmetics creating regulatory demand pull right now. Non-catalytic proteins represent the largest addressable market of the four, driven by avian flu disruptions to egg supply and chronic lactoferrin shortages in infant nutrition. Hydroxy acids, anchored by the 3-HP to acrylic acid pathway, are the brownfield play, integrating into existing chemical infrastructure to serve a seven-million-ton acrylic acid market.

The report draws a line that most biotech coverage blurs. Peptides, non-catalytic proteins, and specialty terpenes compete on function, not price. Biology's advantage here is not cost reduction but access to molecules that chemical synthesis cannot reliably produce, including stereocontrol, novel bioactivities, and compositions free of allergens and PFAS. Hydroxy acids and platform terpenes like isoprene compete on cost, and the path there runs through scale economics, feedstock security, and brownfield integration. AI-driven design tools are compressing discovery timelines across both tracks, enabling multi-property lead optimization in two to three wet-lab rounds rather than eight to twelve.

The report's call to action is specific and stakeholder-segmented. For CPG brands and chemical companies, the ask is binding offtake commitments before major capital is deployed, with sourcing decisions elevated from procurement to C-suite strategy. For investors, the argument is that industrial biomanufacturing sits between venture and infrastructure risk, requiring blended structures that combine equity for innovation with debt and strategic capital for scale. For policymakers, the ask is regulatory streamlining and first-of-a-kind facility support through loan guarantees.

The underlying argument is coordination, not invention. The technical innovations exist. The challenge is aligning fragmented demand, connecting stakeholders across the value chain, de-risking capital deployment, and accelerating qualification cycles.

SynBioBeta 2026 in San Jose this May is precisely the kind of room where this argument needs to land. The message Cradle and their AB4S partners will bring to that stage is about which molecules first, which infrastructure tracks in parallel, which commitments unlock the next ones. By 2031, the coalition projects specialty terpenes and cosmetics peptides generating over one hundred million dollars in combined revenue, with the first brownfield 3-HP plants operating under CPG offtake agreements. That timeline begins with decisions made in rooms like the one SynBioBeta assembles. The plan is ready. The question is whether the industry is.